Form 4: Third Harmonic Bio Director Thomas P. Soloway Acquires 20,000 Stock Options

Director Thomas P. Soloway acquired 20,000 stock options in Third Harmonic Bio, Inc. on June 6, 2024.

Summary

• On June 6, 2024, Thomas P. Soloway, a director of Third Harmonic Bio, Inc., acquired 20,000 stock options.
• The options have an exercise price of $13.85.
• The options vest fully on the earlier of June 6, 2025, or the next annual meeting of the Issuer's stockholders, contingent on continued service to the Issuer.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While option grants can be seen as positive, this is a routine filing.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on the director's continued service to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The acquisition of stock options by a director could potentially align the director's interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates